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Poster Session I S255combination with Cy 1500mg/m2 (Vino-Cy) is also an effective mo-
bilization regimen which is postulated to be better tolerated.
There have been no studies to our knowledge comparing Vino –
Cy with Cy as a mobilization regimen. In our institution, Cy with
GCSF was the mobilization regimen of choice before 2007. Vinor-
elbine - Cy gained preference since late 2006.We performed a retro-
spective analysis of mobilisation outcomes using Vino- Cy at the
doses described above compared to Cy at our institution.
Methods: Patient data was extracted from our institutional database.
Eight patients underwent mobilization using the Cy-GCSF regimen
while 37 patients had Vino-Cymobilization using GCSF or Pegfilgras-
tim.
Results:The median age of the Vino-Cy patients at the time of har-
vest was 54 years, 12 patients were female and the median weight was
60.5 Kg. Themedian age of the Cy patients was 55 years and two pa-
tients were female, the median weight was 60 Kg. A greater median
CD34+ stem cell collection and a shorter median time to completion
of harvest was seen using Vino-Cy compared to Cy (Table 1). There
was also minimal variability in the timing of the harvest for the Vino-
Cy group as suggested by a standard deviation of 0.63.
Table. Mobilisation Outcomes with Vino-Cy and Cy
Day of Protocol No. of Days taken
Harvest Took Place to harvestCyCD34+/KgCyVino-Cy Vino-Cy Vino-CyMedian 9 2 3 12.8 5.5
Mean 8.5 1.8 2.4 13.2 7.8
Minimum 7 1 1 5.4 0.48
Maximum 9 3 0.94 32.5 6.39Discussion. Our data suggest that vinorelbine-Cy is superior to
Cy based on the higher CD34+ stem cell collection (more than ade-
quate for tandem transplant) and earlier completion of harvesting.
The timing of harvest is also highly predictable with Vino-Cy. Pro-
spective analyses are required to determine if Vinorelbine-Cy mobi-
lization confers a survival benefit over Cy.137
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Introduction:TMA is a rare condition that has been associated with
CMV infection in solid organ and allogeneic stem cell transplant re-
cipients. Very little is known about TMA in ASCT recipients.
Methods: We retrospectively reviewed the medical records of all
ASCT recipients at our institution between April 2008 and June
2010 with a positive quantitative plasma polymerase chain reaction
test (qPCR) for CMV deoxyribonucleic acid (DNA). For a diagnosis
of CMV-related TMA we required the presence of schistocytes on
peripheral smear, laboratory evidence of hemolysis and ongoing
CMV infection. We excluded those with other known causes for
TMA (disseminated intravascular coagulation, drugs, malignant hy-
pertension and others).
Results: During the time period examined, 1254 patients with he-
matological cancer underwent melphalan-based ASCT. Reactiva-
tion of CMV was documented in 190 patients (131 within the first
6 months after ASCT, and 59 .6 months after ASCT while receiv-
ing non-myeloablative chemotherapy). Peripheral schistocytosis was
noted in 18 of the 190 patients (9.5%) of whom 13were excluded due
to the presence of other potential causes of TMA, leaving 5 patients
qualified as having CMV-related TMA. All 5 patients had multiple
myeloma, with a median age of 56 years (range 48-67 years), and
a male to female ratio of 2:3. CMV-related TMA developed at a me-
dian of 21 days after ASCT and presented with altered mental status
(3), acute renal failure requiring hemodialysis (3), hepatitis (2), myo-
cardial infarction, bilateral ischemic stroke (1). The clinical manifes-tations of CMV infection in these five patients included
thrombocytopenia (5), fever (4), diarrhea (4), pancytopenia (3) and
pneumonitis (1). The mean CMV qPCR at TMA diagnosis was
7250 DNA copies/ml (range 1250 to 11800 DNA copies/ml). Three
patients died at a mean of eight days after diagnosis (range 5-13 days)
with persistent CMV infection by CMV qPCR while receiving gan-
ciclovir and/or foscarnet. One of the two survivors responded to gan-
ciclovir alone while the other patient received ganciclovir and
rituximab and underwent plasmapheresis. Both survivors cleared
their CMV infection.
Conclusion:CMV-relatedTMA is a rare but serious and potentially
fatal complication in ASCT recipients. This condition should be
considered in the differential diagnosis of TMA because timely ini-
tiation of anti-viral therapy may improve outcome.138
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Background: Autologous stem cell transplantation (ASCT) is
a treatment option for refractory or relapsed Hodgkin lymphoma
(HL). The epidemiology of infectious complications following
ASCT in this population are unknown, thus we set out to identify
the incidence and prevalence of infections in patients with HL re-
ceiving an ASCT.
Patients and Methods: We retrospectively reviewed records from
patients who underwent ASCT for HL at our institution between 1/
1996 and 8/2009. Patients received acyclovir, neutropenic and PCP
prophylaxis and weremonitoredweekly for pp65 antigenemia early af-
ter ASCT.The probability of infections was assessed using cumulative
incidence estimates and incidence rates were calculated with 95% con-
fidence intervals (CI) estimated using a Poisson distribution.
Results: A total of 171 patients had a median of 673 days of follow-
up post-ASCT (range: 357-1592 days). There were a total of 622 in-
fections that occurred in 151 patients (89%), of which 323/622
(51.9%) were proven/probable cases. The cumulative incidence of
any infection was 58% at 90 days and 81% at 1 year after ASCT.
In the early period, bacteremia and CMV pp65 antigenemia were
most frequent, occurring in 29% and 31% (CMV seropositives) re-
spectively by day 90. Serious invasive infections occurred in 20/177
(11%) patients (24 total infections: GNR bacteremia 7; invasive fun-
gal disease 6; lower tract infection 5; typhlitis 2; CMV disease 2;
HHV-6 encephalitis 1; PCP 1). Sinopulmonary infections made up
more than 50% of all events, with cumulative incidence ranging
from 17% (sinusitis) to 15% (respiratory virus infections) at 1 year.
Conclusions: Infections are a frequent complication following
ASCT for HL with serious invasive disease occurring in 11% of pa-
tients. Bacterial infections and CMV antigenemia were the most
common infections in the early post-transplant period, while sino-
pulmonary infections were the most prevalent late infections.139
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Dominant cardiac involvement by primary systemic amyloidosis
(AL) precludes effective AL treatment and is associated with short
survival. Three patients who presented with severe cardiac dysfunc-
tion as their major AL manifestation underwent orthotopic heart
